PLK1 and myelodysplastic syndrome: Rigosertib inhibits both PLK1 and phosphatidylinositol 3-kinase (PI3K) and has been investigated in clinical trials against solid tumors and hematological malignancies such as myelodysplastic syndrome (MDS) [19, 20].